Vertex Pharmaceuticals Incorporated (VRTX) Receives Consensus Rating of “Buy” from Analysts
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have been given an average rating of “Buy” by the thirty-one research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and twenty-three have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $167.76.
Several analysts have recently commented on VRTX shares. BidaskClub lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 28th. Zacks Investment Research upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price target on the stock in a research report on Tuesday, July 4th. Cowen and Company reiterated a “market perform” rating and issued a $105.00 price target on shares of Vertex Pharmaceuticals in a research report on Thursday, July 6th. Jefferies Group LLC started coverage on shares of Vertex Pharmaceuticals in a research report on Monday, July 10th. They issued a “buy” rating and a $155.00 price target on the stock. Finally, Stifel Nicolaus increased their price target on shares of Vertex Pharmaceuticals from $130.00 to $154.00 and gave the company a “buy” rating in a research report on Tuesday, July 18th.
WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) Receives Consensus Rating of “Buy” from Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/25/vertex-pharmaceuticals-incorporated-vrtx-receives-consensus-rating-of-buy-from-analysts.html.
Vertex Pharmaceuticals (NASDAQ VRTX) opened at 151.11 on Wednesday. The company has a 50-day moving average of $153.75 and a 200-day moving average of $138.51. Vertex Pharmaceuticals has a 52 week low of $71.46 and a 52 week high of $167.85. The stock has a market capitalization of $38.10 billion, a price-to-earnings ratio of 145.16 and a beta of 1.73.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.06 by $0.33. The business had revenue of $544.10 million for the quarter, compared to analyst estimates of $489.95 million. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The company’s quarterly revenue was up 26.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.24 earnings per share. Analysts anticipate that Vertex Pharmaceuticals will post $1.62 earnings per share for the current year.
In other news, CEO Jeffrey M. Leiden sold 11,063 shares of the stock in a transaction on Monday, July 31st. The shares were sold at an average price of $152.81, for a total value of $1,690,537.03. Following the completion of the sale, the chief executive officer now owns 268,455 shares of the company’s stock, valued at $41,022,608.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David Altshuler sold 1,796 shares of the stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $160.00, for a total transaction of $287,360.00. Following the completion of the sale, the executive vice president now directly owns 107,807 shares of the company’s stock, valued at approximately $17,249,120. The disclosure for this sale can be found here. Insiders sold 43,748 shares of company stock valued at $6,734,021 in the last three months. Company insiders own 1.80% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Teachers Advisors LLC grew its holdings in Vertex Pharmaceuticals by 48.6% during the 1st quarter. Teachers Advisors LLC now owns 510,373 shares of the pharmaceutical company’s stock valued at $55,809,000 after purchasing an additional 166,998 shares in the last quarter. NorthCoast Asset Management LLC acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at $782,000. Delta Lloyd Asset Management N.V. acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at $3,285,000. Prudential Financial Inc. grew its holdings in Vertex Pharmaceuticals by 12.8% during the 2nd quarter. Prudential Financial Inc. now owns 444,725 shares of the pharmaceutical company’s stock valued at $57,312,000 after purchasing an additional 50,350 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its holdings in Vertex Pharmaceuticals by 89.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 14,463 shares of the pharmaceutical company’s stock valued at $1,863,000 after purchasing an additional 6,836 shares in the last quarter. 92.93% of the stock is owned by institutional investors.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.